We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AnaptysBio Inc | NASDAQ:ANAB | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.17 | -0.46% | 37.06 | 20.00 | 38.00 | 38.85 | 36.89 | 37.71 | 288,205 | 23:41:03 |
“Our wholly-owned pipeline continues to make progress with the recent initiation of our imsidolimab GEMINI-1 Phase 3 trial in GPP and anticipated initiation of our rosnilimab AZURE alopecia areata Phase 2 trial during the remainder of 2021,” said Hamza Suria, president and chief executive officer of AnaptysBio. “We believe the recent royalty monetization transaction with Sagard validates the future revenue stream anticipated from JEMPERLI sales and further supports AnaptysBio’s capital-efficient business model.”
Imsidolimab (Anti-IL-36 Receptor) Program
Rosnilimab (Anti-PD-1 Agonist) Program
ANB032 (Anti-BTLA Modulator) Program
GSK Partnered Programs
Third Quarter Financial Results
Financial Guidance
Following the anticipated closing of the Sagard royalty monetization transaction by the end of 2021, we anticipate ending 2021 with approximately $600 million in cash and will continue to operate in a capital-efficient manner.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The Company’s proprietary anti-inflammatory pipeline includes imsidolimab, its anti-IL-36R antibody, previously referred to as ANB019, for the treatment of dermatological inflammatory diseases, including generalized pustular psoriasis, or GPP, acne, and hidradenitis suppurativa; rosnilimab, its anti-PD-1 agonist program, previously referred to as ANB030, for the treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated; and its BTLA modulator program, ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GSK, including an anti-PD-1 antagonist antibody (JEMPERLI (dostarlimab-gxly) GSK4057190), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386), and an inflammation collaboration with Bristol-Myers Squibb, including an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in clinical development.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from our clinical trials, including imsidolimab’s Phase 2 clinical trials in acne, and hidradenitis suppurativa, rosnilimab’s Phase 1 healthy volunteer clinical trial and Phase 2 clinical trial in alopecia areata, and ANB032’s healthy volunteer Phase 1 trial; the timing of the initiation of imsidolimab’s GPP Phase 3 clinical trials; including the risk that the transaction with Sagard may not close when expected, or at all, the risk that commercial sales of JEMPERLI may not reach expected levels, under the GSK collaboration; and our projected 2021 cash burn and cash runway. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Contact:Dennis MulroyAnaptysBio, Inc. 858.732.0201dmulroy@anaptysbio.com
AnaptysBio, Inc.Consolidated Balance Sheets (in thousands, except par value data)(unaudited)
September 30, 2021 | December 31, 2020 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 336,328 | $ | 250,456 | |||
Receivables from collaborative partners | 761 | — | |||||
Short-term investments | 37,736 | 143,197 | |||||
Prepaid expenses and other current assets | 11,759 | 2,908 | |||||
Short-term restricted cash | 60 | — | |||||
Total current assets | 386,644 | 396,561 | |||||
Property and equipment, net | 2,413 | 1,783 | |||||
Operating lease right-of-use assets | 19,778 | 344 | |||||
Long-term investments | 15,242 | 17,546 | |||||
Other long-term assets | 258 | 258 | |||||
Long-term restricted cash | — | 60 | |||||
Total assets | $ | 424,335 | $ | 416,552 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 5,717 | $ | 4,217 | |||
Accrued expenses | 14,075 | 15,262 | |||||
Current portion of operating lease liability | 1,097 | 342 | |||||
Total current liabilities | 20,889 | 19,821 | |||||
Operating lease liability, net of current portion | 19,838 | — | |||||
Stockholders’ equity: | |||||||
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at September 30, 2021 and December 31, 2020, respectively | — | — | |||||
Common stock, $0.001 par value, 500,000 shares authorized, 27,454 shares and 27,356 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively | 27 | 27 | |||||
Additional paid in capital | 672,996 | 660,665 | |||||
Accumulated other comprehensive loss | (200 | ) | (4 | ) | |||
Accumulated deficit | (289,215 | ) | (263,957 | ) | |||
Total stockholders’ equity | 383,608 | 396,731 | |||||
Total liabilities and stockholders’ equity | $ | 424,335 | $ | 416,552 |
AnaptysBio, Inc. Consolidated Statements of Operations and Comprehensive Loss(in thousands, except per share data) (unaudited)
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||
Collaboration revenue | $ | 20,890 | $ | — | $ | 62,164 | $ | 15,000 | |||||||
Operating expenses: | |||||||||||||||
Research and development | 22,221 | 19,542 | 71,720 | 58,458 | |||||||||||
General and administrative | 5,432 | 4,794 | 16,101 | 13,766 | |||||||||||
Total operating expenses | 27,653 | 24,336 | 87,821 | 72,224 | |||||||||||
Loss from operations | (6,763 | ) | (24,336 | ) | (25,657 | ) | (57,224 | ) | |||||||
Other income, net: | |||||||||||||||
Interest income | 64 | 625 | 363 | 3,583 | |||||||||||
Other income (expense), net | 33 | (56 | ) | 36 | 64 | ||||||||||
Total other income, net | 97 | 569 | 399 | 3,647 | |||||||||||
Net loss | (6,666 | ) | (23,767 | ) | (25,258 | ) | (53,577 | ) | |||||||
Unrealized loss on available for sale securities | (24 | ) | (494 | ) | (196 | ) | (79 | ) | |||||||
Comprehensive loss | $ | (6,690 | ) | $ | (24,261 | ) | $ | (25,454 | ) | $ | (53,656 | ) | |||
Net loss per common share: | |||||||||||||||
Basic and diluted | $ | (0.24 | ) | $ | (0.87 | ) | $ | (0.92 | ) | $ | (1.96 | ) | |||
Weighted-average number of shares outstanding: | |||||||||||||||
Basic and diluted | 27,436 | 27,316 | 27,397 | 27,286 | |||||||||||
1 Year AnaptysBio Chart |
1 Month AnaptysBio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions